Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Esperion Therapeutics' Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $0.20 EPS.
Other analysts have also issued reports about the stock. StockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $6.75.
View Our Latest Stock Report on ESPR
Esperion Therapeutics Trading Up 6.3 %
Shares of NASDAQ:ESPR traded up $0.10 during trading on Tuesday, hitting $1.69. 3,260,581 shares of the company were exchanged, compared to its average volume of 4,053,618. Esperion Therapeutics has a fifty-two week low of $1.56 and a fifty-two week high of $3.94. The stock has a market cap of $332.99 million, a price-to-earnings ratio of -2.64 and a beta of 1.01. The firm has a fifty day moving average price of $1.96 and a two-hundred day moving average price of $2.08.
Hedge Funds Weigh In On Esperion Therapeutics
Large investors have recently made changes to their positions in the company. Mackenzie Financial Corp grew its holdings in Esperion Therapeutics by 116.1% in the 4th quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company's stock valued at $315,000 after buying an additional 76,965 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after acquiring an additional 16,100 shares during the period. Rafferty Asset Management LLC acquired a new position in shares of Esperion Therapeutics in the fourth quarter valued at about $82,000. ProShare Advisors LLC increased its position in Esperion Therapeutics by 75.2% during the fourth quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company's stock worth $138,000 after acquiring an additional 26,843 shares during the period. Finally, Nuveen Asset Management LLC raised its stake in Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. Institutional investors own 47.39% of the company's stock.
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also

Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.